TNSN99132A1 - Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause - Google Patents

Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause

Info

Publication number
TNSN99132A1
TNSN99132A1 TNTNSN99132A TNSN99132A TNSN99132A1 TN SN99132 A1 TNSN99132 A1 TN SN99132A1 TN TNSN99132 A TNTNSN99132 A TN TNSN99132A TN SN99132 A TNSN99132 A TN SN99132A TN SN99132 A1 TNSN99132 A1 TN SN99132A1
Authority
TN
Tunisia
Prior art keywords
osteoporosis
prevention
composition
treatment
menopause syndrome
Prior art date
Application number
TNTNSN99132A
Other languages
English (en)
Inventor
Cavazza Claudio
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of TNSN99132A1 publication Critical patent/TNSN99132A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

-UNE COMPOSITION QUI PEUT PRENDRE LA FORME D'UN SUPPLEMENT DIETETIQUE OU D'UN MEDICAMENT EFFECTIF EST DIVULGUEE PAR CETTE INVENTION ET COMPREND COMME INGREDIENTS ACTIFS ET CARACTERISTIQUES LE PROPIONYL L- CARNITINE ET L'ISOFLAVONE (FGENISTEIN), DESTINEE A LA PREVENTION ET/OU AU TRAITEMENT THERAPEUTIQUE DE L'OSTEOPOROSE ET DU SYNDROME DE MENOPAUSE
TNTNSN99132A 1998-06-23 1999-06-23 Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause TNSN99132A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98RM000417A IT1299191B1 (it) 1998-06-23 1998-06-23 Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa

Publications (1)

Publication Number Publication Date
TNSN99132A1 true TNSN99132A1 (fr) 2005-11-10

Family

ID=11406005

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99132A TNSN99132A1 (fr) 1998-06-23 1999-06-23 Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause

Country Status (27)

Country Link
US (1) US6335038B1 (fr)
EP (1) EP1089742B1 (fr)
JP (1) JP4430233B2 (fr)
KR (1) KR20010071541A (fr)
CN (1) CN1306434A (fr)
AR (1) AR018924A1 (fr)
AT (1) ATE228367T1 (fr)
AU (1) AU755272B2 (fr)
BR (1) BR9911440A (fr)
CA (1) CA2334875C (fr)
DE (1) DE69904172T2 (fr)
DK (1) DK1089742T3 (fr)
EE (1) EE200000741A (fr)
ES (1) ES2188177T3 (fr)
HU (1) HU224957B1 (fr)
IL (1) IL140163A0 (fr)
IS (1) IS5764A (fr)
IT (1) IT1299191B1 (fr)
MA (1) MA26655A1 (fr)
NO (1) NO20006431L (fr)
NZ (1) NZ508877A (fr)
PL (1) PL192118B1 (fr)
PT (1) PT1089742E (fr)
SK (1) SK19292000A3 (fr)
TN (1) TNSN99132A1 (fr)
TR (1) TR200003735T2 (fr)
WO (1) WO1999066913A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1302863B1 (it) * 1998-11-13 2000-10-10 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante e preventiva di alterazionitrombotiche e aterosclerotiche comprendente una carnitina ed un
US6476010B2 (en) * 2000-03-10 2002-11-05 Hill's Pet Nutrition Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
US20010039296A1 (en) * 2000-03-23 2001-11-08 Debasis Bagchi Method and composition for preventing or reducing the symptoms of menopause
US20020076470A1 (en) 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
IT1317079B1 (it) 2000-12-21 2003-05-26 Sigma Tau Ind Farmaceuti Uso della isovaleril l-carnitina per la preparazione di un medicamentoper la prevenzione e cura dell'osteoporosi.
IL157367A0 (en) * 2001-03-09 2004-02-19 Nestle Sa Composition improving age-related physiological deficits and increasing longevity
JP4646491B2 (ja) * 2001-03-15 2011-03-09 ディーエスエム アイピー アセッツ ビー．ブイ． イソフラボンおよび多価不飽和脂肪酸の組合せを含む、骨粗鬆症を予防するための組成物
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
AU2003207429A1 (en) * 2002-02-15 2003-09-04 N.V. Nutricia Use of genistein in the manufacture of a medicament for the treatment of osteoporosis and obesity, and compositions containing genistein in combination with vitamin d and k
KR100542478B1 (ko) * 2002-08-28 2006-01-11 한경대학교 산학협력단 석류 유래 피토에스트로겐을 함유하는 건강기능식품
WO2004026287A1 (fr) * 2002-09-09 2004-04-01 Nestec S.A. Composition par voie orale d'amelioration de la qualite de la peau
KR100520408B1 (ko) * 2003-03-25 2005-10-10 주식회사 태평양 비만개선용 조성물
KR101143719B1 (ko) * 2003-05-27 2012-05-09 디에스엠 아이피 어셋츠 비.브이. 신규한 기능식품 조성물 및 그의 용도
JP2005187454A (ja) * 2003-12-05 2005-07-14 Sankyo Co Ltd ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
AU2005211165B8 (en) * 2004-01-28 2011-07-14 Nestec S.A. Nutritional composition for improving skin condition and preventing skin diseases
WO2005074905A1 (fr) * 2004-02-03 2005-08-18 Kotosugi Inc. Agent therapeutique/preventif pour l'osteoporose contenant comme composant de l'isotaxiresinol derive de taxus yunnanensis
AU2005224017B2 (en) * 2004-03-17 2010-12-16 Société des Produits Nestlé S.A. Compositions and methods for reducing or preventing obesity
CN100351248C (zh) * 2004-07-05 2007-11-28 南京大学 染料木素衍生物及其制法和用途
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
DE102004060314A1 (de) * 2004-12-08 2006-08-31 Beiersdorf Ag Wirkstoffkombinationen aus einem oder mehreren Isoflavonoiden und Carnitin und/oder einem oder mehreren Acyl-Carnitinen
WO2006071919A2 (fr) 2004-12-29 2006-07-06 Hill's Pet Nutrition, Inc. Methodes permettant d'inhiber un declin des facultes d'apprentissage et/ou de la memoire chez les animaux
BRPI0519851A2 (pt) * 2005-01-10 2017-05-30 Hormos Medical Ltd uso de uma lignana para a manufatura de uma composição para prevenir ou aliviar os sintomas relacionados à deficiência de estrogênio
DK1904044T3 (da) * 2005-07-08 2013-05-13 Sigma Tau Ind Farmaceuti Anvendelse af en kombination omfattende L-carnitin, eller alkanoyl-L-carnitin, en fedtopløselig benzoquinon og en omega-3 polyumættet fedtsyre til fremstilling af et kosttilskud, eller et medikament, til behandling af hornhindesygdomme
CA2615060C (fr) 2005-07-14 2016-06-21 Hill's Pet Nutrition, Inc. Procede permettant de prolonger la vie d'animaux
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
CN101365431A (zh) * 2005-10-14 2009-02-11 帝斯曼知识产权资产管理有限公司 包含白藜芦醇的营养药物组合物的新颖用途
RU2420091C2 (ru) * 2005-11-02 2011-06-10 Нестек С.А. Изофлавоновая композиция для снижения накопления телесного жира у млекопитающего мужского пола, ее применение, способ снижения накопления жира
WO2007100671A2 (fr) * 2006-02-28 2007-09-07 Nestec S.A. Compositions et méthodes pour induire une croissance osseuse et inhiber une perte osseuse
EP1993579A2 (fr) * 2006-02-28 2008-11-26 Council of Scientific and Industrial Research Composition pharmaceutique pour la prevention/ le traitementde troubles osseux et son processus d'elaboration
WO2007116052A1 (fr) * 2006-04-12 2007-10-18 Unilever Plc Composition orale à dha/génistéine pour ameliorer des proprietes de la peau
EP2004169B1 (fr) * 2006-04-12 2012-08-08 Unilever PLC Composition orale comprenant un acide gras polyinsaturé et de l'acide salicylique destinée à produire un effet anti-inflammatoire dans la peau
PL2189155T3 (pl) * 2006-04-12 2016-07-29 Unilever Nv Doustna kompozycja o przeciwstarzeniowym działaniu na skórę
US20080108696A1 (en) * 2006-08-02 2008-05-08 Brinton Roberta D Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases
US8680140B2 (en) * 2006-08-02 2014-03-25 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
US20080200441A1 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators associated pharmaceutical compositions and methods of use
EP2343292B1 (fr) 2008-09-10 2014-08-06 Asahi Glass Company, Limited Nouveau dérivé de prostaglandine i2
US20110091435A1 (en) * 2008-10-24 2011-04-21 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of hair loss
EA019237B1 (ru) * 2008-11-11 2014-02-28 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Соединения, пригодные для лечения целлюлита
KR101158856B1 (ko) 2009-05-12 2012-06-25 한국생명공학연구원 콩잎 추출물 또는 이의 분획물을 유효성분으로 함유하는 비만, 고지혈증, 동맥경화, 지방간, 당뇨 또는 대사증후군의 예방 또는 치료용 조성물
BR112012022632B1 (pt) * 2010-03-08 2020-03-31 Kaken Pharmaceutical Co., Ltd. Medicamento compreendendo Agonista de ep4
ES2670836T3 (es) * 2010-06-16 2018-06-01 Alfasigma S.P.A. Acetil-carnitina para uso en un método para incrementar la neurogénesis en el tejido neuronal
WO2012011572A1 (fr) * 2010-07-23 2012-01-26 国立大学法人大阪大学 Agent thérapeutique pour insuffisance cardiaque diastolique
IT201700116392A1 (it) * 2018-04-03 2019-10-03 Composizione per somministrazione orale aventi benefico effetto sulla salute della donna in menopausa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1275434B (it) * 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
AU6141498A (en) * 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases

Also Published As

Publication number Publication date
DE69904172T2 (de) 2003-08-28
CA2334875C (fr) 2009-05-12
MA26655A1 (fr) 2004-12-20
AR018924A1 (es) 2001-12-12
ES2188177T3 (es) 2003-06-16
ITRM980417A1 (it) 1999-12-23
BR9911440A (pt) 2001-03-20
CA2334875A1 (fr) 1999-12-29
PL345030A1 (en) 2001-11-19
WO1999066913A3 (fr) 2000-04-20
IL140163A0 (en) 2002-02-10
DK1089742T3 (da) 2003-03-24
HU224957B1 (en) 2006-04-28
SK19292000A3 (sk) 2001-08-06
PL192118B1 (pl) 2006-09-29
JP4430233B2 (ja) 2010-03-10
NZ508877A (en) 2002-09-27
AU755272B2 (en) 2002-12-05
EP1089742B1 (fr) 2002-11-27
CN1306434A (zh) 2001-08-01
AU4390999A (en) 2000-01-10
ITRM980417A0 (it) 1998-06-23
US6335038B1 (en) 2002-01-01
HUP0102879A2 (hu) 2002-03-28
JP2002518437A (ja) 2002-06-25
HUP0102879A3 (en) 2002-12-28
IT1299191B1 (it) 2000-02-29
DE69904172D1 (de) 2003-01-09
KR20010071541A (ko) 2001-07-28
EP1089742A2 (fr) 2001-04-11
WO1999066913A2 (fr) 1999-12-29
PT1089742E (pt) 2003-04-30
EE200000741A (et) 2002-04-15
NO20006431D0 (no) 2000-12-15
NO20006431L (no) 2001-02-22
ATE228367T1 (de) 2002-12-15
IS5764A (is) 2000-12-08
TR200003735T2 (tr) 2001-03-21

Similar Documents

Publication Publication Date Title
TNSN99132A1 (fr) Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause
TNSN99163A1 (fr) COMPOSITION ANTIOXYDANTE COMPRENANT L'ACETYL-CARNITINE ET L'ACIDE α -LIPOIQUE QUI AMELIORE L'UTILISATION METABOLIQUE DU GLUCOSE
TNSN99135A1 (fr) Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression
CA2339221A1 (fr) Extraits de chrysanteme-matricaire (tanacetum parthenium) utilises contre les troubles inflammatoires
BR0008059A (pt) Composições de valdecoxib
BG104727A (en) Pharmaceutical composition of topiramate
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
LU91281I2 (fr) Preotact-hormone parathyroïde
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
HK1025737A1 (en) Treatment of multiple sclerosis through ingestion of copolymer-1
LV12766A (lv) Composition of l-dopa esters
KR950031059A (ko) 골다공증 치료용 약제학적 조성물
KR880003620A (ko) 치료용 합성물 및 치료법(Therapeutic Composition and Method)
DE69802113T2 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
TNSN00083A1 (fr) Une composition contenant un carnitine et un phosphate d'inositol utilisee comme supplement dietetique ou medicament
IL159241A0 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
TNSN01076A1 (fr) Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant
CA2226140A1 (fr) Composes pour traiter ou prevenir l'osteosporose et les symptomes associes avec la menopause
TNSN00216A1 (fr) Une composition pour la prevention et/ou pour le traitement des troubles dus aux anomalies du metabolisme des lipides, comportant la propionyl l-carnitine et le chitosane
CA2429793A1 (fr) Ameliorateur de l'effet therapeutique de l'interferon
FR2710844B1 (fr) Composition pour le traitement ou la prévention de l'herpès.
FR2374044A1 (fr) Agent anti-diabetique oral contenant une sulfonyluree et une kinine
DE60215812D1 (de) Orale zusammensetzungen zur behandlung von adipösen, nicht diabetischen säugetieren, einschliesslich menschen
KR960000248A (ko) 골대사 질환 치료제
BR9811293A (pt) Composições para o tratamento da alopecia, do hirsutismo feminino ou da seborréia, ou uma composição para a prevenção da metástase óssea causada por câncer prostático, e, usos de um composto e de n-{1-metil-1-(4-metoxifenil)etil}-3-oxo-4-aza-5-alfa-and rost-1-eno-17-beta-c arboxamida